-
Measures aim to boost consumption
2022-01-26
As Spring Festival draws near, a recent guideline aims to make consumption a more forceful driver of growth this year, experts said.
-
BDA and BUCM join hands
2022-01-25
The Beijing Economic and Technological Development Area (BDA) and Beijing University of Chinese Medicine (BUCM) signed a strategic cooperation agreement on Jan 18.
-
BDA's health service network expands
2022-01-25
The spacious and bright hospital environment, comfortable and convenient medical conditions, and smart medical facilities... The Zhongxin Branch of Yizhuang Hospital has opened.
-
NDRC moots sophisticated distribution
2022-01-25
China is speeding up efforts to build a modern distribution system during the 14th Five-Year Plan (2021-25) period as it is key to the implementation of the new dual-circulation development pattern and bolstering high-quality development, China's top economic regulator said on Monday.
-
Virus fears deal blow to overseas buying agents
2022-01-25
A customer in Tianjin canceled an order with a purchasing agent based in Australia a few days ago, the agent said, because of fears that the delivery of a parcel from overseas would cause their health code to turn from green to yellow.
-
Nation to sustain growth in cross-border e-commerce despite challenges
2022-01-24
Cross-border e-commerce in China will sustain its growth momentum throughout the year despite various challenges, propelled by new business forms such as overseas warehouses, technological advances and growing demand for stay-at-home products, experts and business leaders said.
-
Incense-making highlights 'Dialogue with Da Vinci' exhibit
2022-01-21
The immersive light and shadow art exhibition Time Treasures - Dialogue with Da Vinci at the Beijing Economic and Technological Development Area (BDA) on Jan 18, 2022 was filled with refreshing aroma of herbs.
-
BDA pharmaceutical-developed medicine approved for clinical trials in US
2022-01-21
JAB-2485, independently developed by the Beijing Economic & Technological Development Area (BDA) enterprise Jacobio Pharmaceuticals, was approved in the United States for clinical trial application for treatment of various advanced solid tumors on Jan 17, 2022.